Shares of Viking Therapeutics (VKTX) are down $2.70, or 6%, to $44.00 in pre-market trading following Merck (MRK) and Chinese biopharmaceutical company Hansoh Pharma’s announcement earlier that ...

Recognized for their exceptional products, Viking provides free standing ranges, range tops, ovens, refrigeration of all kinds, and much more. They have re-engineered their products and they are ...

Barclays analyst Brandt Montour downgraded Viking Holdings (VIK) to Equal Weight from Overweight with an unchanged price target of $49. The firm cites the stock’s recent rally for the downgrade.